Document:

EX-10.6.4

 Exhibit 10.6.4 
 FOIA CONFIDENTIAL TREATMENT REQUESTED 
 PORTIONS OF THE EXHIBIT MARKED BY
[**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 Amendment No. 21 
 To the 

WorldView3 Instrument Purchase Agreement #60151 
 This Amendment No. 21 (“Amendment”) to WorldView 3 Instrument Purchase Agreement #60151 (the “Agreement”) is entered into by and between DigitalGlobe, Inc.
(“DigitalGlobe”), a corporation organized and existing under the laws of the State of Delaware, with a place of business at 1601 Dry Creek Drive, Suite 260, Longmont, CO 80503; and ITT Space Systems, LLC., a Delaware corporation with its
principal offices located at 1447 St. Paul Street, Rochester, New York, 14621 (“Contractor”). As used in this Agreement, “Party” means either DigitalGlobe or ITT, as appropriate, and “Parties” means DigitalGlobe and
ITT. 
 WHEREAS, DigitalGlobe and ITT entered into the WorldView3 Instrument Purchase Agreement #60151
(“Agreement”) on August 27, 2010; 
 Now, THEREFORE, the parties hereby agree to amend the Agreement to
incorporate the following Engineering Change Proposal (“ECP”) (Reference ITT Exelis Proposal 13-116 – [**Redacted**] dated April 2, 2013—included as Attachment #1): 

Problem: 
 BATC changed the
[**Redacted**] than was used for WV2. The current configuration needs to be modified so that the [**Redacted**]. BATC confirmed the change in part number and design, which were only recently communicated to Exelis. 

Scope: 
 ITT Exel is tasks covered
by Contract Modification #21 shall include re-design of the [**Redacted**]. ITT Exelis will use the current [**Redacted**]. Effort shall include an update of [**Redacted**]. 

The WV3 Instrument to Spacecraft ICD rev D shall be updated by BATC to show the [**Redacted**]. 

Price: The [**Redacted**] modification is $18,000. 
 Payment Milestone: 
 Add Milestone #157: [**Redacted**]—Completion in
April 2013. 
 DigitalGlobe Proprietary and Confidential 

Use or disclosure of data is subject to the restriction on the title page of this document. 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 SUMMARY 
 The value for these ECPs is $18,000, outlined in the following table: 
  

							
	 Change #
	  	 Change Description
	  	$	 
	021	  	[**Redacted**]	  	$	18,000.00	  
		  		  	  
	  
	 
		  	TOTAL	  	$	18,000.00	  
		  		  	  
	  
	 

 Contract Value Summary 
  

					
	 Previous Contract Value
	  	$	168,812,033.00	  
	 ECPs
	  	$	18,000.00	  
		  	  
	  
	 
	 New Contract Value
	  	$	168,830,033.00	  
		  	  
	  
	 

 Unless otherwise expressly provided herein, all other terms and conditions of the Agreement shall remain in full force
and effect. 
 This Amendment No. 21 is hereby executed and agreed to by DigitalGlobe and ITT Exelis and shall be binding and effective as
of the last date executed below. 
  

					
	ITT Space Systems, LLC	 		 	DigitalGlobe, Inc.
			
	 /s/ [**Redacted**]
	 		 	 /s/ Neal T. Anderson

	 Signature
	 		 	 Signature

	Name: [**Redacted**]	 		 	Name: Neal T. Anderson
	Contract Officer	 		 	Title: V.P., Technology Development
	Date: April 18, 2013	 		 	Date: April 18, 2013

  

DigitalGlobe Proprietary and Confidential 
 Use or disclosure of data is subject to the restriction on the title page of this document. 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 Attachment 1 

ITT Exelis is Proposal 13-116 – [**Redacted**] 
 Dated April 2, 2013 

  

DigitalGlobe Proprietary and Confidential 
 Use or disclosure of data is subject to the restriction on the title page of this document. 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 ITT EXELIS 

 

							
		 		 		 	[**Redacted**]
		 		 		 	Contract Manager
		 		 		 	 ITT Space Systems, LLC

Rochester. New York 4606

		 		 		 	[**Redacted**]
		 		 		 	[**Redacted**]
		 		 		 	[**Redacted**]

 April 2, 2013 
 DigitalGlobe, Inc. Sent via e-mail to: 
 [**Redacted**] 

Subject: Proposal 13-116 – [**Redacted**] 
 Dear Jim: 
 ITT Space Systems, LLC, a subsidiary of Exelis, Inc. (Exelis) is submitting this
[**Redacted**] proposal associated with the [**Redacted**] (details attached to cover). 
 Contract 

[**Redacted**]—$18,000 
 Period
of Performance 
 This activity will be incorporated in the existing Master Program Schedule 

Payment Terms 
 This proposal is subject
to a mutually agreed milestone payment being added to the current Program Milestone Payment schedule. 
 Exelis would like to
proposal the following milestone payments: 
  

	 	•	 	 #157: [**Redacted**] – April 2013 ($18,000) 

 Payment terms are net 30 days from the date of the invoice. 
 U.S. Export Law, as contained in the
International Traffic in Arms Regulations (ITAR), is applicable to the information provided with the finished optics. This technical information is not to be placed in the public domain, exported from the U.S., given to any foreign person in the
U.S. or re-exported without the prior specific written authorization of Exelis, Inc. and the U.S. Department of State. Any ITT Space Systems, LLC agreement to provide technical data, defense services, and/or hardware to any foreign party under this
contract is contingent upon receipt of proper U.S. Government export authorizations. In the event a license permit it cannot be obtained to export the product and/or data included in this order, or it is later revoked, this order is null and void
and of no effect. 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 ITT EXELIS 
 ITT Space Systems, LLC appreciates the opportunity to provide this proposal. Should you have any questions or require additional information, please feel free to contact me directly. 

Regards, 
 [**Redacted**] 

[**Redacted**] 
 Contract Manager 
 ITT Space Systems, LLC 

Rochester, New York 14606  
 [**Redacted**] 
 [**Redacted**] 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 ITT EXELIS 

WV3—Revision of [**Redacted**] 
 Problem: 
 Ball changed the [**Redacted**] than was used for WV2. The current configuration
needs to be modified so that the [**Redacted**]. 
 BATC confirmed the change in part number and design, which were not communicated to
Exelis. 
 [**Redacted**] 

Scope: 
 Tasks required include re-design of
[**Redacted**]. Exelis will use current 
 [**Redacted**]. Effort also includes update of [**Redacted**].  

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 Modification No. 22 

To the 

WorldView3 Instrument Purchase Agreement #60151 
 This Modification No. 22 (“the Modification”) to WorldView 3 Instrument Purchase Agreement #60151 (“the Agreement”) is entered into by and between DigitalGlobe, Inc.
(“DigitalGlobe”), a corporation organized and existing under the laws of the State of Delaware, with a place of business at 1601 Dry Creek Drive, Suite 260, Longmont, CO 80503; and ITT Space Systems, LLC, (since renamed ITT Exelis LLC) a
Delaware corporation with its principal offices located at 1447 St. Paul Street, Rochester, New York, 14621 (“Contractor”). As used in this Agreement, “Party” means either DigitalGlobe or Contractor, as appropriate, and
“Parties” means DigitalGlobe and Contractor. 
 WHEREAS, DigitalGlobe and Contractor entered into the
WorldView3 Instrument Purchase Agreement #60151 (“Agreement”) on August 27, 2010; 
 Now, THEREFORE, the
parties hereby agree to amend the Agreement to incorporate the following Engineering Change Proposal (“ECP”) (Reference ITT Exelis Proposal 13-157 – [**Redacted**] dated April 26, 2013- included as Attachment #1):

 Problem: 
 Due to
rework of the DPU, DigitalGlobe wishes to add [**Redacted**]. 
 Scope: 

Contractor shall add [**Redacted**]. The powerpoint charts contained in Attachment 1 document the additional [**Redacted**] as discussed
during a telecom held on April 18th 2013. 
 Price: The [**Redacted**] for this modification is $72,000. 

Period of Performance: This added testing will occur in April and shall be completed no later than May 31, 2013. 

Payment Milestone: 
 This activity will result in one (1) additional milestone. 
 Milestone #158-
Completion of [**Redacted**] 

  

DigitalGlobe Proprietary and Confidential 
 Use or disclosure of data is subject to the restriction on the title page of this document. 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 SUMMARY 
 The value for this ECP is a [**Redacted**] of $72,000, outlined in the following table: 
  

							
	 Change#
	  	 Change Description
	  	$	 
	 022
	  	 [**Redacted**]
	  	$	72,000.00	  
		  		  	  
	  
	 
		  	 TOTAL
	  	$	72,000.00	  
		  		  	  
	  
	 

 Contract Value Summary 
  

					
	 Previous Contract Value
	  	$	168,830,033.00	  
	 ECP
	  	$	72,000.00	  
		  	  
	  
	 
	 New Contract Value
	  	$	168,902,033.00	  
		  	  
	  
	 

 Unless otherwise expressly provided herein, all other terms and conditions of the Agreement shall remain in full force
and effect. 
 This Modification No. 22 is hereby executed and agreed to by DigitalGlobe and Contractor and shall be binding and effective
as of the last date executed below. 
  

					
	ITT Space Systems, LLC	  		 	DigitalGlobe, Inc.
			
	 /s/ [**Redacted**]
	  		 	 /s/ Neal T. Anderson

	Signature	  		 	Signature
	Name: [**Redacted**]	  		 	Name: Neal T. Anderson
	Contract Manager	  		 	Title: V.P., Technology Development
	Date: May 1, 2013	  		 	Date: April 30, 2013

  

DigitalGlobe Proprietary and Confidential 
 Use or disclosure of data is subject to the restriction on the title page of this document. 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 Attachment 1 

ITT Exelis Proposal13-157- [**Redacted**]. 
 Dated April 26, 2013 

  

DigitalGlobe Proprietary and Confidential 
 Use or disclosure of data is subject to the restriction on the title page of this document. 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 ITT EXELlS 

 

							
		  		  		  	 [**Redacted**]

Contract Manager
 ITT Space Systems,
LLC
 Rochester, New York 14606

[**Redacted**]

[**Redacted**]

[**Redacted**]

 April 26, 2013 
 DigitalGlobe, Inc. 
 Sent via sharepoint to: 

[**Redacted**] 
 [**Redacted**]

 Subject: Revised Proposal 13-157- [**Redacted**] 
 Dear Jim: 
 ITT Space Systems, LLC, a subsidiary of Exelis, Inc. (Exelis) is pleased to submit
this [**Redacted**]. The SOW for this effort is attached. 
 CONTRACT TYPE: 

The [**Redacted**] for this task order is $72,000 
 STATEMENT OF WORK: 
 ITT Exelis shall add [**Redacted**]. The attached powerpoint
charts document the additional [**Redacted**] as discussed during a telecom held on April 18th 2013. 
 INVOICING/BILLING:

 This activity will result in one (1) additional milestone proposed as: 
 158- Completion of [**Redacted**]. 
 Payment terms are net 30 days from the date of the
invoice. A 2% per month charge shall be applied to any payments for any past due balance carried beyond 30 calendar days. 
 U.S. Export
Law, as contained in the International Traffic in Arms Regulations (ITAR), is applicable to the information provided with the finished optics. This technical information is not to be placed in the public domain, exported from the U.S., given to any
foreign person in the U.S. or re-exported without the prior specific written authorization of Exelis, Inc. and the U.S. Department of State. Any ITT Space Systems, LLC agreement to provide technical data, defense services, and/or hardware to any
foreign party under this contract is contingent upon receipt of proper U.S. Government export authorizations. In the event a license permit cannot be obtained to export the product and/or data included in this order, or it is later revoked, this
order is null and void and of no effect. 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 ITT EXELIS 
 ITT Space Systems, LLC appreciates the opportunity to provide this proposal. Should you have any questions or require additional information, please feel free to contact me directly. 

Regards, 
 [**Redacted**] 

[**Redacted**] 
 Contract Manager

 ITT Space Systems, LLC Rochester, New York 14606 
 [**Redacted**] 
 [**Redacted**] 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 ITT EXELIS 

WV-3 [**Redacted**] 
 April 18, 
 2013 

[**Redacted**] 

  

					
	ITT Exelis Geospatial Systems            [**Redacted**]	  	2	  	ITT Exelis Proprietary

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

			
	ITT Exelis Geospatial Systems	 	ITT Exelis Proprietary

 WV-3 [**Redacted**] 
 Proposed [**Redacted**]: 
  

	•	 	 [**Redacted**] 

  

	•	 	 [**Redacted**] 

  

					
	ITT Exelis Geospatial Systems            [**Redacted**]	  	3	  	ITT Exelis Proprietary

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 ITT EXELIS
             WV-3 [**Redacted**] 
  

					
	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]

  

					
	ITT Exelis Geospatial Systems            [**Redacted**]	  	4	  	ITT Exelis Proprietary

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 

             WV-3 [**Redacted**] 

[**Redacted**] 

  

					
	ITT Exelis Geospatial Systems            [**Redacted**]	  	5	  	ITT Exelis Proprietary

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 Modification No. 23 

To the 

WorldView3 Instrument Purchase Agreement #60151 
 This Modification No. 23 (“the Modification”) to WorldView 3 Instrument Purchase Agreement #60151 (“the Agreement”) is entered into by and between DigitalGlobe, Inc.
(“DigitalGlobe”), a corporation organized and existing under the laws of the State of Delaware, with a place of business at 1601 Dry Creek Drive, Suite 260, Longmont, CO 80503; and ITT Space Systems, LLC., (since renamed ITT Exelis LLC) a
Delaware corporation with its principal offices located at 1447 St. Paul Street, Rochester, New York, 14621 (“Contractor”). As used in this Agreement, “Party” means either DigitalGlobe or Contractor, as appropriate, and
“Parties” means DigitalGlobe and Contractor. 
 WHEREAS, DigitalGlobe and Contractor entered into the
WorldView3 Instrument Purchase Agreement #60151 (“Agreement”) on August 27, 2010; 
 Now, THEREFORE, the
parties hereby agree to amend the Agreement to incorporate the following Engineering Change Proposal (“ECP”) (Reference ITT Exelis Proposal 11-128 – [**Redacted**], February 4th, 2013 – included as Attachment #1):

 Problem: 
 While
considerable analysis and testing has been done during the course of the instrument build, DigitalGlobe desires a fully assembled [**Redacted**]. 
 Scope: 
 Contractor shall perform a test as described in the ITT Exelis proposal,
attachment #1. The [**Redacted**]. 
 Price: The [**Redacted**] for this modification is $145,000. However Exelis
agrees to reimburse the [**Redacted**] ($145,000) if test #1 reveals [**Redacted**] per the Success Criteria. 
 Period of
Performance: This added testing will occur before the ship date in late June or July, 2013. As this test is at the request of DigitalGlobe, the contractual delivery date of ATP + 1050 days shall be changed to ATP + 1057 days. 

  

DigitalGlobe Proprietary and Confidential 
 Use or disclosure of data is subject to the restriction on the title page of this document. 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 Payment Milestone: 

This activity will result in one (1) additional milestone, Milestone #159 – [**Redacted**] Successfully Complete, which
shall be payable after successful test complete in July 2013. 
 SUMMARY 
 The value for this ECP is a [**Redacted**] of $145,000, outlined in the following table: 
  

							
	 Change #
	  	 Change Description
	  	$	 
	 023
	  	[**Redacted**]	  	$	145,000.00	  
		  		  	  
	  
	 
		  	TOTAL	  	$	145,000.00	  
		  		  	  
	  
	 

 Contract Value Summary 
  

					
	 Previous Contract Value
	  	$	168,902,033.00	  
	 ECP
	  	$	145,000.00	  
		  	  
	  
	 
	 New Contract Value
	  	$	169,047,033.00	  
		  	  
	  
	 

 Unless otherwise expressly provided herein, all other terms and conditions of the Agreement shall remain in full force
and effect. 
 This Modification No. 23 is hereby executed and agreed to by DigitalGlobe and Contractor and shall be binding and effective
as of the last date executed below. 
  

					
	ITT Exelis LLC.	 		 	DigitalGlobe, Inc.
			
	  
	 		 	  

	Signature	 		 	Signature
			
	 [**Redacted**]
	 		 	 Steve Linn

	Name	 		 	Name
			
	 [**Redacted**]
	 		 	 V.P. Space Systems

	Title	 		 	Title
			
	 May 15, 2013
	 		 	 May 14, 2013

	Date	 		 	Date

  

DigitalGlobe Proprietary and Confidential 
 Use or disclosure of data is subject to the restriction on the title page of this document. 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 Attachment 1 

ITT Exelis Proposal 11-128 – [**Redacted**]. 
 Dated February 4th, 2013 

  

DigitalGlobe Proprietary and Confidential 
 Use or disclosure of data is subject to the restriction on the title page of this document. 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 

 
  

			
		  	[**Redacted**]
		  	Contract Officer
		  	ITT Space Systems, LLC
		  	     Rochester, New
 York 14606 
 [**Redacted**]

		  	[**Redacted**]
		  	[**Redacted**]

 February 4, 2013 
 DigitalGlobe, Inc. Sent via e-mail to: 
 [**Redacted**] 

Subject: Revised Bid #11-128- [**Redacted**] 
 Dear Jim: 
 ITT Space Systems, LLC, a subsidiary of Exelis, Inc. (EXELIS) is pleased to submit this
revised [**Redacted**] proposal associated with [**Redacted**]. 
 EXELIS proposes a [**Redacted**] of $145,000. However,
EXELIS agrees to reimburse the [**Redacted**] ($145,000) if test #1 reveals [**Redacted**] per the Success Criteria. Reimbursement is conditional on test #1 (Main Test: [**Redacted**]) only. Execution of Test #1 (Main Test:
[**Redacted**]) assumes that DG authorizes optimization of the [**Redacted**]. 
 The tests and associated assumptions and exceptions
are described as follows: 
  

	1)	Main Test: [**Redacted**] 

Overview Description 
 The purpose of this test is to demonstrate at the instrument level that [**Redacted**]. This test is not used to verify requirements, however if the test indicates that some [**Redacted**]
and will require further discussion and disposition between Exelis and DigitalGlobe. 
 General Test Description

 For at least the [**Redacted**]. The images shall be saved in case further inspection is required. 

Test Procedure and Success Criteria 
 Testing will be conducted per the process outlined in Appendix A. Success criteria is per this process and is summarized below 

 

	 	•	 	 [**Redacted**]. 

  

	 	•	 	 [**Redacted**]. 

  
 EXELIS
PROPRIETARY INFORMATION SYSTEMS 
 CONFIDENTIAL INFORMATION 

[This document is ITAR controlled. Use or disclosure of this information must be handled accordingly].

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 

 
 Note: For all of the above testing, [**Redacted**]. 

 

	2)	Shutter Test 

Overview Description 
 The purpose of this test is to demonstrate that the shutter is [**Redacted**]. This test is not used to verify requirements, however if the test indicates that the shutter is [**Redacted**]
and will require further discussion and disposition between Exelis and DigitalGlobe. 
 General Test Description

 In the [**Redacted**]. This test includes: 

 

	 	•	 	 Definition of test configuration and requirements 

  

	 	•	 	 Test configuration hardware 

  

	 	•	 	 Setup and deconfiguration of [**Redacted**] 

  

	 	•	 	 Test execution, analysis, and documentation 

 Test Procedure 
  

	 	1.	[**Redacted**]. 

  

	 	2.	[**Redacted**]. 

  

	 	3.	[**Redacted**]. 

  

	 	4.	[**Redacted**]. 

[**Redacted**]. 
 Success Criteria 
 [**Redacted**]. Any significant deviations shall
be discussed with DigitalGlobe along with hypotheses for root cause. 
  

	3)	[**Redacted**] Test 

Overview Test Description 
 The purpose of this test is to provide DigitalGlobe with data sufficient to characterize the [**Redacted**]. 
 In the [**Redacted**]. This test includes: 
  

	 	•	 	 [**Redacted**] 

  

	 	•	 	 [**Redacted**] 

  

	 	•	 	 [**Redacted**] 

 Test Procedure 
  

	 	1.	[**Redacted**]. 

  

	 	2.	[**Redacted**]. 

  

  
 EXELIS
PROPRIETARY INFORMATION SYSTEMS 
 CONFIDENTIAL INFORMATION 

[This document is ITAR controlled. Use or disclosure of this information must be handled accordingly].

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 

 
 Success Criteria 
 This is a characterization test only. This test shall be considered successful when the [**Redacted**] has been delivered to DigitalGlobe. 

Proposal Assumptions: 
  

	 	•	 	 If collected data indicates a possible failure to meet a specific Instrument requirement, the issue must be evaluated and dispositioned by Exelis and
DigitalGlobe. 

  

	 	•	 	 These tests will be quantitative in that the [**Redacted**]. 

 

	 	•	 	 The baseline data for Test #1 will be the [**Redacted**]. 

 

	 	•	 	 EXELIS anticipates that these tests (Test #1, Test #2 and Test #3) will occur after the completion of the [**Redacted**].

  

	 	•	 	 DG will provide EXELIS with the associated [**Redacted**]. 

 

	 	•	 	 DG will provide EXELIS with any required [**Redacted**]. 

Test Conditions: 
  

	 	•	 	 The [**Redacted**]. 

  

	 	•	 	 The test data to be provided consists of [**Redacted**]. 

 

	 	•	 	 EXELIS will conduct the initial data assessment for each test and will provide the data to DG for their evaluation. EXELIS anticipates that
[**Redacted**]. 

 Schedule implications: 

 

	 	•	 	 DigitalGlobe will change the contractual delivery date from ATP + 1050 days to ATP + 1057 days. (See paragraph 3.1.a of the WV3 Statement of Work,
document number 10329744). The rationale for this change is based upon our estimate that we will require a minimum of 5 days of critical path time (7 calendar days) to complete all of the test and data analysis activities. This estimate assumes that
initial setup of the [**Redacted**]. 

  

	 	•	 	 If our analysis of the complete test configuration indicates a [**Redacted**]. If this occurs, DigitalGlobe will work cooperatively with EXELIS
to define a mutually agreeable delivery date. 

 APPENDIX A— DETAILED TEST PROCESSES 

Process for WV-3 Instrument [**Redacted**]: 
  

	 	1.	[**Redacted**] 

  

	 	2.	[**Redacted**]. 

  

	 	3.	Exelis will perform [**Redacted**]. 

  

	 	4.	Exelis will compare the [**Redacted**]. 

  
 EXELIS
PROPRIETARY INFORMATION 
 SYSTEMS CONFIDENTIAL INFORMATION 

[**Redacted**] 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 

 
  

	 	5.	[**Redacted**]. 

  

	 	6.	Steps 4 and 5 will determine [**Redacted**]. 

  

	 	7.	[**Redacted**]. 

  

	 	8.	For all of the above testing, the [**Redacted**]. 

  

	 	9.	[**Redacted**]. 

  
 EXELIS
PROPRIETARY INFORMATION 
 SYSTEMS CONFIDENTIAL INFORMATION 

[**Redacted**] 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 

 
 [**Redacted**] 
  

	 	1.	[**Redacted**] 

 U.S. Export Law, as
contained in the International Traffic in Arms Regulations (ITAR), is applicable to the information provided with the finished optics. This technical information is not to be placed in the public domain, exported from the U.S., given to any foreign
person in the U.S. or re-exported without the prior specific written authorization of ITT Space Systems, LLC, a subsidiary of Exelis, Inc. and the U.S. Department of State. Any ITT Space Systems, LLC agreement to provide technical data, defense
services, and/or hardware to any foreign party under this contract is contingent upon receipt of proper U.S. Government export authorizations. In the event a license permit cannot be obtained to export the product and/or data included in this order,
or it is later revoked, this order is null and void and of no effect. 
 ITT Space Systems, LLC appreciates the opportunity to provide this
proposal. Should you have any questions or require additional information, please feel free to contact me directly. 
 Regards, 

[**Redacted**] 
 [**Redacted**]

 Contract Manager 
 ITT
Space Systems, LLC 
 [**Redacted**] 
 [**Redacted**] 

  
 EXELIS
PROPRIETARY INFORMATION 
 SYSTEMS CONFIDENTIAL INFORMATION 

[**Redacted**] 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 Modification No. 24 

To the 

WorldView3 Instrument Purchase Agreement #60151 
 This Modification No. 24 (“the Modification”) to WorldView 3 Instrument Purchase Agreement #60151 (“the Agreement”) is entered into by and between DigitalGlobe, Inc.
(“DigitalGlobe”), a corporation organized and existing under the laws of the State of Delaware, with a place of business at 1601 Dry Creek Drive, Suite 260, Longmont, CO 80503; and ITT Space Systems, LLC., (since renamed ITT Exelis LLC) a
Delaware corporation with its principal offices located at 1447 St. Paul Street, Rochester, New York, 14621 (“Contractor”). As used in this Agreement, “Party” means either DigitalGlobe or Contractor, as appropriate, and
“Parties” means DigitalGlobe and Contractor. 
 WHEREAS, DigitalGlobe and Contractor entered into the
WorldView3 Instrument Purchase Agreement #60151 (“Agreement”) on August 27, 2010; 
 Now, THEREFORE, the
parties hereby agree to amend the Agreement to incorporate the following Engineering Change Proposal (“ECP”) (Reference ITT Exelis Proposal 12-504- [**Redacted**], Phase 2, dated January 21st, 2013- included as Attachment #1):

 Background: 
 Contractor had
planned to [**Redacted**] independently. While this approach has worked fairly well in the past, this WV3 Telescope is far more complicated from a [**Redacted**] standpoint. Thus DigitalGlobe requested that some effort be expended to
determine if a more [**Redacted**] could be done. Thus a Statement of Work was developed between DigitalGlobe and the Contractor and a proposal generated. Contract Modification 19 funded initial planning and development (Phase 1) and this
modification funds actually performing that test (phase 2). 
 Scope: 
 Contractor shall perform tests as described in the ITT Exelis proposal, Phase 2, attachment #1. The entire WV3 assembled [**Redacted**] and tests done to verify operation. 

Price: The [**Redacted**] for this modification is $682,000. 
 Period of Performance: This added testing will occur before the ship date in late June or July, 2013. 
 Payment Milestone: 
 This activity will result in two (2) additional milestones:

  

DigitalGlobe Proprietary and Confidential 
 Use or disclosure of data is subject to the restriction on the title page of this document. 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 Milestone #160 – [**Redacted**]—$600,000 —testing complete 

Expected completion: July 2013 
 Milestone
#161[**Redacted**]—$82,000—shall be billable when all testing, analysis, thermal model updates, final model delivery, Consent to break review, and delivery of technical documentation, as is described in the proposal, has been done.
Expected completion date: September 2013 
 SUMMARY 
 The value for this ECP is a [**Redacted**] of $682,000, outlined in the following table: 
  

							
	 Change#
	  	 Change Description
	  	$	 
	 024
	  	[**Redacted**] Phase 2	  	$	682,000.00	  
		  	TOTAL	  	$	682,000.00	  

 Contract Value Summary 
  

					
	 Previous Contract Value
	  	$	169,047,033.00	  
	 ECP
	  	$	682,000.00	  
	 New Contract Value
	  	$	169,729,033.00	  

 Unless otherwise expressly provided herein, all other terms and conditions of the Agreement shall remain in full force
and effect. 
 This Modification No. 24 is hereby executed and agreed to by DigitalGlobe and Contractor and shall be binding and effective
as of the last date executed below. 
  

					
	ITT Exelis LLC.	  		 	DigitalGlobe, Inc.
	  
	  		 	  

	Signature	  		 	Signature
			
	 [**Redacted**]
	  		 	 Steve Linn

	Name	  		 	Name
			
	 [**Redacted**]
	  		 	 V.P. Space Systems

	Title	  		 	Title
			
	 May 16, 2013
	  		 	 May 14, 2013

	Date	  		 	Date

  

DigitalGlobe Proprietary and Confidential 
 Use or disclosure of data is subject to the restriction on the title page of this document. 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 Attachment 1 

ITT Exelis Proposal 12-504 – [**Redacted**] Proposal January 21st, 2013 

  

DigitalGlobe Proprietary and Confidential 
 Use or disclosure of data is subject to the restriction on the title page of this document. 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

					
	

	 		 	 [**Redacted**]
 Contract
Manager
 ITT Space Systems, LLC Rochester, New York 14606
 [**Redacted**]
 [**Redacted**]

[**Redacted**]

 January 21, 2013 
 DigitalGlobe, Inc. Sent via 
 e-mail to: 
 [**Redacted**] 
 Subject: Proposal12-504- [**Redacted**] Proposal Revised 1/18/2013

 Reference: [**Redacted**] Statement of Work (SOW) dated 1/18/2013 
 Dear Jim: 
 ITT Space Systems, LLC, a subsidiary of Exelis, Inc. (Exelis) is pleased to submit
this [**Redacted**] proposal associated with the [**Redacted**]. This revision incorporates a rewritten statement of work entitled [**Redacted**] dated 1/18/2013, and reduces the price of Phase 2 commensurate with the reduction
in test duration. 
 The revised SOW is based on the SOW delivered to Exelis by DigitalGlobe on 1/14/2013. To facilitate your review, updates
made to the DG document by Exelis have been highlighted in blue font. The SOW includes a schedule integrating [**Redacted**]. This schedule demonstrates [**Redacted**] of slack against the [**Redacted**] original contract
delivery date. 
 Contract 

[**Redacted**]—$1,600,000 
 Phase 1—$918,000 
 Phase 2—$ 682,000 

Period of Performance 
 Phase 1 of this
effort starts at Authorization to Proceed, assumed on January 21, 2013, and includes all planning, design, material procurements, procedures, scripting, manufacturing instructions, and pre-test thermal modeling and analysis. Phase 1 also
includes delivery of the [**Redacted**] and the Test Plan Review meeting with DigitalGlobe. 
 Phase 2 of this effort, assumed to start
on April 18th 2013, includes shipping, [**Redacted**]. Phase 2 also includes the [**Redacted**]. 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

  
 

 
 Payment Terms 
 This proposal is subject to a mutually agreed milestone payments being added to the current Program Milestone Payment schedule. 
 Exelis would like to proposal the following milestone payments: 
 Phase 1

  

	 	•	[**Redacted**] 

	 	•	[**Redacted**] 

 Phase 2

  

	 	•	[**Redacted**] 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 Payment terms are net 30 days from the date of the invoice. A 2% per month charge shall be applied
to any payment carried beyond 30 calendar days. 
 U.S. Export Law, as contained in the International Traffic in Arms Regulations (ITAR), is
applicable to the information provided with the finished optics. This technical information is not to be placed in the public domain, exported from the U.S., given to any foreign person in the U.S. or re-exported without the prior specific written
authorization ofExelis, Inc. and the U.S. Department of State. Any ITT Space Systems, LLC agreement to provide technical data, defense services, and/or hardware to any foreign party under this contract is contingent upon receipt of proper U.S.
Government export authorizations. In the event a license permit cannot be obtained to export the product and/or data included in this order, or it is later revoked, this order is null and void and of no effect. 

ITT Space Systems, LLC appreciates the opportunity to provide this proposal. Should you have any questions or require additional information, please feel
free to contact me directly. 
 Regards, 
 [**Redacted**] 
 Contract Manager 
 ITT Space Systems, LLC 
 Rochester, New York 14606  

[**Redacted**] 
 [**Redacted**]

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 Statement of Work 
 WV-3 [**Redacted**] 
 RESTRICTION ON USE,
PUBLICATION, OR DISCLOSURE OF PROPRIETARY INFORMATION 
 This document contains information proprietary and confidential
to the Exelis Inc., or a third party whom Exelis may have a legal obligation to protect such information from unauthorized disclosure, use, or duplication. Any disclosure, use, or duplication of this document or of any of the information contained
herein for other than the specific purpose for which it was disclosed is expressly prohibited, except as Exelis has otherwise agreed in writing. All copies of this document are the sole property of Exelis and will be returned promptly upon request.

 [**Redacted**] 
 [**Redacted**] 

			
	FOIA CONFIDENTIAL TREATMENT REQUESTED	 	2

 PORTIONS OF THE EXHIBIT
MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 Table of Contents 

 

					
	 1. Task Objectives
	  	 	3	  
	 2. [**Redacted**]
	  	 	3	  
	 2.1. [**Redacted**]
	  	 	3	  
	 2.2. [**Redacted**]
	  	 	3	  
	 2.3. Functional Checks
	  	 	3	  
	 3. [**Redacted**]
	  	 	3	  
	 4. Test Limitations & Constraints
	  	 	4	  
	 4.1. Units Not Present During Test
	  	 	4	  
	 4.1.1. [**Redacted**]
	  	 	4	  
	 4.1.2. [**Redacted**]
	  	 	4	  
	 4.2. Units Present But Not Operated During Test
	  	 	4	  
	 4.2.1. [**Redacted**]
	  	 	4	  
	 4.2.2. [**Redacted**]
	  	 	4	  
	 4.2.3. [**Redacted**]
	  	 	4	  
	 4.2.4. [**Redacted**]
	  	 	4	  
	 4.3. Limited Use of Redundant Electronics
	  	 	4	  
	 5. Technical Approach
	  	 	5	  
	 5.1. Design & Analysis
	  	 	5	  
	 5.2. Test Thermal Telemetry
	  	 	5	  
	 5.3. STE Requirements & Fabrication
	  	 	5	  
	 5.4. Test Support
	  	 	5	  
	 5.5. Test Approach
	  	 	5	  
	 5.6. Model Correlation
	  	 	6	  
	 6. Reviews and Deliverables
	  	 	6	  
	 6.1. Test Plan Review (Phase 1)
	  	 	6	  
	 6.2. Test Readiness Review (TRR) (Phase 2)
	  	 	6	  
	 6.3. Consent to Break (CTB) Review (Phase 2)
	  	 	6	  
	 6.4. Deliverables
	  	 	6	  
	 7. Facility and Schedule
	  	 	6	  
	 8. Schedule
	  	 	6	  
	 8.1. Phase 1
	  	 	6	  
	 8.2. Phase 2
	  	 	6	  
	 8.3. Critical Path Impact
	  	 	6	  
	 8.4. Integrated Schedule
	  	 	7	  

  
 EXELIS
PROPRIETARY INFORMATION 
 SYSTEMS CONFIDENTIAL INFORMATION 

[**Redacted**] 

			
	FOIA CONFIDENTIAL TREATMENT REQUESTED	 	3

 PORTIONS OF THE EXHIBIT
MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

	1.	Task Objectives 

 The task
objectives are [**Redacted**]. 
  

	2.	[**Redacted**] 

 The
[**Redacted**] test will have three main parts: 
 2.1. [**Redacted**] 

This is the main portion of the test that provides the majority of data needed for post-test model correlation. The [**Redacted**]
will be determined during Phase 1. 
 2.2. [**Redacted**] 

[**Redacted**] 
 2.3. Functional Checks 
 Limited functional checks will be performed
[**Redacted**]. 
  

	3.	[**Redacted**] 

 The test
data will be used to [**Redacted**] 

  
 EXELIS
PROPRIETARY INFORMATION 
 SYSTEMS CONFIDENTIAL INFORMATION 

[**Redacted**] 

			
	FOIA CONFIDENTIAL TREATMENT REQUESTED	 	4

 PORTIONS OF THE EXHIBIT
MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

	4.	Test Limitations & Constraints 

 4.1. Units Not Present During Test 
 4.1.1. [**Redacted**]

 [**Redacted**] 
 4.1.2. [**Redacted**] 
 [**Redacted**] 

4.2. Units Present But Not Operated During Test 
 4.2.1. [**Redacted**] 
 [**Redacted**] 

[**Redacted**] 
 [**Redacted**] 
 4.2.2. [**Redacted**] 

[**Redacted**] 
 4.2.3. [**Redacted**] 
 [**Redacted**] 

4.2.4. [**Redacted**] 
 [**Redacted**] 
 4.3. Limited Use of Redundant Electronics

 [**Redacted**] 

  
 EXELIS
PROPRIETARY INFORMATION 
 SYSTEMS CONFIDENTIAL INFORMATION 

[**Redacted**] 

			
	FOIA CONFIDENTIAL TREATMENT REQUESTED	 	5

 PORTIONS OF THE EXHIBIT
MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 [**Redacted**] 

 

	5.	Technical Approach 

 The
following sections provide an overview of our technical approach: 
 5.1. Design & Analysis 

[**Redacted**] 
 [**Redacted**] 
 [**Redacted**] 

5.2. Test Thermal Telemetry 
 [**Redacted**] 
 [**Redacted**] 

5.3. STE Requirements & Fabrication 
 All required STE is included in the scope of this task, [**Redacted**]. 

5.4. Test Support 
 [**Redacted**] 
 5.5. Test Approach 

[**Redacted**] 

[**Redacted**] 
 A
Consent-to-Proceed huddle will be held with the test team at the end of the [**Redacted**]. 
 [**Redacted**] 

[**Redacted**] 

  
 EXELIS
PROPRIETARY INFORMATION 
 SYSTEMS CONFIDENTIAL INFORMATION 

[**Redacted**] 

			
	FOIA CONFIDENTIAL TREATMENT REQUESTED	 	6

 PORTIONS OF THE EXHIBIT
MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 [**Redacted**] 
 Figure 1: [**Redacted**] 
 [**Redacted**] 

[**Redacted**] 
 5.6. Model Correlation 
 After the [**Redacted**]. 

 

	6.	Reviews and Deliverables 

6.1. Test Plan Review (Phase 1) 
 A test plan review will be held no later than [**Redacted**] to test execution. The test plan must be mutually agreed to by Exelis and DigitalGlobe before test execution. 

6.2. Test Readiness Review (TRR) (Phase 2) 
 A TRR will be held [**Redacted**]. 
 6.3. Consent to Break (CTB) Review
(Phase 2) 
 A CTB review will be held at the [**Redacted**]. Consent to Proceed huddles will be held with the test
team at key transition points in the test to gain agreement to move between defined test conditions. 
 6.4. Deliverables

 A test plan shall be delivered to DigitalGlobe as part of Phase 1. [**Redacted**] will be delivered to DigitalGlobe
as part of Phase 2. 
  

	7.	Facility 

 The
[**Redacted**] will be conducted in our [**Redacted**]. At this time, this chamber is capable, operational and available for this test. 
  

	8.	Schedule 

 8.1. Phase 1

 Phase 1 of this effort starts at [**Redacted**] and the Test Plan Review meeting with DigitalGlobe. 

8.2. Phase 2 
 Phase 2 of this effort, assumed to start on [**Redacted**]. Phase 2 also includes the TRR, Consent to Break review, and delivery of updated thermal technotes. 

8.3. Critical Path Impact 
 The [**Redacted**]. 

  
 EXELIS
PROPRIETARY INFORMATION 
 SYSTEMS CONFIDENTIAL INFORMATION 

[**Redacted**] 

			
	FOIA CONFIDENTIAL TREATMENT REQUESTED	 	7

 PORTIONS OF THE EXHIBIT
MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 8.4. Integrated Schedule 

Figure 2 displays the [**Redacted**], and includes a column designating line items as Phase 1 or Phase 2. Integration of
[**Redacted**]. 
 [**Redacted**] 
 Figure 2: [**Redacted**] 

  
 EXELIS
PROPRIETARY INFORMATION 
 SYSTEMS CONFIDENTIAL INFORMATION 

[**Redacted**] 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 Modification No. 25 

To the 

WorldView3 Instrument Purchase Agreement #60151 
 This Modification No. 25 (“the Modification”) to WorldView 3 Instrument Purchase Agreement #60151 (“the Agreement”) is entered into by and between DigitalGlobe, Inc.
(“DigitalGlobe”), a corporation organized and existing under the laws of the State of Delaware, with a place of business at 1601 Dry Creek Drive, Suite 260, Longmont, CO 80503; and ITT Space Systems, LLC., (since renamed ITT Exelis LLC) a
Delaware corporation with its principal offices located at 1447 St. Paul Street, Rochester, New York, 14621 (“Contractor”). As used in this Agreement, “Party” means either DigitalGlobe or Contractor, as appropriate, and
“Parties” means DigitalGlobe and Contractor. 
 WHEREAS, DigitalGlobe and Contractor entered into the
WorldView3 Instrument Purchase Agreement #60151 (“Agreement”) on August 27, 2010; 
 Now, THEREFORE, the
parties hereby agree to amend the Agreement to incorporate the following Specification Update to Revision 8- included as Attachment #1): 

Scope: 
 Multiple changes based on
further definition from testing or capabilities, has been agreed upon between the Parties. These changes are spelled out in the Specification change section of the Specification Revision 8 document. 

Price: The [**Redacted**] for this modification is zero dollars. 
 Period of Performance: Specification Revision 8 shall become the ruling technical document form this date forward or until a new revision is agreed upon. Specification Revision 8 supersedes all
previous revisions. 
 Payment Milestone: 
 No new payment Milestones are included in this revision. 
 SUMMARY 

The value for this Specification Revision is outlined in the following table: 

 

							
	 Change#
	  	 Change Description
	  	$	 
	 025
	  	Specification Revision 8	  	$	0.00	  
		  		  	  
	  
	 
		  	TOTAL	  	$	0.00	  
		  		  	  
	  
	 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 Contract Value Summary 

 

					
	 Previous Contract Value
	  	$	169,047,033.00	  
	 Specification Revision 8
	  	$	0.00	  
	 New Contract Value
	  	$	169,047,033.00	  

 Unless otherwise expressly provided herein, all other terms and conditions of the Agreement shall remain in full force
and effect. 
 This Modification No. 25 is hereby executed and agreed to by DigitalGlobe and Contractor and shall be binding and effective
as of the last date executed below. 
  

			
	ITT Exelis LLC.	    	DigitalGlobe, Inc.
		
	  
 Signature
	    	  
 Signature

		
	[**Redacted**]	    	Steve Linn
	  
 Name
	    	  
 Name

		
	[**Redacted**]	    	V.P. Space Systems
	  
 Title
	    	  
 Title

		
	May 16, 2013	    	May 14, 2013
	  
 Date
	    	  
 Date

 DigitalGlobe Proprietary and Confidential 

Use or disclosure of data is subject to the restriction on the title page of this document. 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 Attachment 1 

Specification Revision 8 
 DigitalGlobe Proprietary and Confidential 
 Use or disclosure of data is
subject to the restriction on the title page of this document. 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 WorldView-3 Instrument 

Specification 
  

			
	 Document #
	  	10329742
	 Revision #
	  	8.0
	 Release Date
	  	8 May 2013
	 Prepared by
	  	Paul Scott
	 Approved by
	  	Keith Constantinides

 [**Redacted**] 
 RESTRICTION ON USE, PUBLICATION, OR DISCLOSURE OF PROPRIETARY INFORMATION 
 This document contains information proprietary and confidential to
DigitalGlobeTM, to its subsidiaries, or to a third party to whom DigitalGlobe may have a legal obligation to
protect such information from unauthorized disclosure, use or duplication. Any disclosure, use or duplication of this document or of any of the information contained herein for other than the specific purpose for which it was disclosed is expressly
prohibited, except as DigitalGlobe may otherwise agree to in writing. This document may only be used for the purpose for which it is provided. All copies of this document are the sole property of DigitalGlobe and will be returned promptly upon
request. 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

 Change Record 

 

									
	 Revision
	  	Date	 	  	Sections	  	 Description of Change

	 1.0
	  	 	8/24/2010	  	  	All	  	Initial Release
				
	 2.0
	  	 	9/23/2010	  	  	2.2.2	  	Eliminated reference to Nextview on Contamination Control Implementation Plan for WV-3 and replaced TBD with document number. Added WV-3 SSS 1553 Command List to Contractor
Documents list.
				
		  				  	3.1.4
 3.3.1

 
 3.3.11.1

3.3.11.3

3.3.11.4

3.3.11.5

3.3.12.2
  

3.3.12.3
  

3.4.1.2
  

3.4.2.3

3.4.3.1
  

3.4.4.3
  

3.5.2
  

3.6.3
  

3.7.1.4
  

3.9.7
  

3.9.11.4.1
  

4.7
	  	 Change [**Redacted**]

Changed [**Redacted**]
  
 Decreased [**Redacted**]
 Increased [[**Redacted**]

Changed number [**Redacted**]
 Dropped
[**Redacted**]
 Increased [**Redacted**]
  

[**Redacted**]
  
 [**Redacted**]
  
 Added
TBR [**Redacted**]
 Maximum [**Redacted**]
  

Added TBR [**Redacted**]
  

States and state [**Redacted**]
  

Replaced previous paragraph with reference [**Redacted**]
 Added TBR [**Redacted**]
  
 [**Redacted**]
  

Eliminated [**Redacted**]
  

Removed the A from 3.4.2.1, 3.4.2.2, and 3.4.2.3. Added T to 3.4.2.2, 3.4.2.3, 3.9.11.1.3.1 and 3.9.11.1.3.2. Removed T from 3.5.4.1.

 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

							
	 Revision
	  	Date	  	Sections	  	 Description of Change

	3.0	  	1/14/2011	  	2.2.3  
 3.1.1
  
 3.1.4
  
 3.2.2.2
  
 3.2.2.3
  
 3.2.2.4
 3.3.7

3.3.11.5
  

3.4.2.3

3.4.4.1

3.4.4.3
  

3.5.2
  

3.6.3
  

3.7.1.4
  

3.9.10

3.9.11.1.8

3.9.11.2

3.9.11.4.1

3.9.11.17.3

4.6.5.8.1
  

4.6.5.10
  

4.6.5.10.1
  

 
  

4.6.5.10.2

4.7
	  	 [**Redacted**]
  

Changed block diagram to include [**Redacted**]
  

Change [**Redacted**]
  
 Added [**Redacted**]
  

Revised [**Redacted**]
  
 Added word “Any” to beginning of d)
 Revised [**Redacted**]

Revised [**Redacted**]
  
 Removed [**Redacted**]
 Replaced [**Redacted**]

Removed TBR, [**Redacted**]
  

Removed TBR [**Redacted**]
  

Removed TBR [**Redacted**]
  

Remove TBR and [**Redacted**]
  

Reworded [**Redacted**]
 Included
[**Redacted**]
 Revised [**Redacted**]
 Deleted [**Redacted**]
 Corrected [**Redacted**]

Added entry to [**Redacted**]
  

Made this section a title only and put content into new 4.6.5.10.1
  

Added this section to include content from previous 4.6.5.10 and [**Redacted**]. Corrected [**Redacted**]

 
 New paragraph entitled [**Redacted**]

Changed entry in [**Redacted**]

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

							
	 Revision
	  	Date	  	Sections	  	 Description of Change

	4.0	  	5/4/2011	  	2.1.1
 2.2.1

 
 2.3

3.2.2.2
 3.3.9
and its
subparagraphs
 3.4.3.1
 3.5.5
  
 3.9.4.3
 3.9.11.2

 
 3.9.11.3.1

 
 3.9.11.4.4

3.9.11.4.5

3.9.11.10

3.9.11.11

3.9.11.15.1

3.9.11.15.4
  

3.9.11.15.5
  

3.9.11.15.6

3.9.11.17

3.9.11.17.1
  

3.9.11.17.2

3.9.11.17.3

4.6.5.7.3

4.6.5.9
  

4.6.5.10.1
  

4.6.5.10.2

4.6.5.12
  

4.7
	  	 Changed [**Redacted**]

Added [**Redacted**]
  
 Clarified that this document is obsolete.
 Inserted word [**Redacted**]

New content replacing Reserved
  

Minor [**Redacted**]
 Deleted reference to
removed section [**Redacted**]
  
 Deleted section

Added new entry to [**Redacted**]
  

Added words [**Redacted**]
  

Replaced section with reference to ICD
 Replaced
section with reference to ICD
 Changed title to remove [**Redacted**]
 Deleted content, changed title to Reserved
 Changed [**Redacted**]

Added sentence requiring DG approval for non-standard parts. Removed sentence regarding mission non-critical parts

Clarified “plastic parts” to mean plastic encapsulated electronic parts.
 Extensively revised.
 Extensively revised.
 Removed first sentence. Added [**Redacted**] to second sentence
 Removed first
sentence.
 Removed first sentence.

Added 2 sentences at end.
 Modified wording of
first paragraph to [**Redacted**]
  
  
 Added clarification to performance parameters [**Redacted**]
  
 Retitled and revised [**Redacted**]
 Changed title and text [**Redacted**]

 
 Updated verification matrix due to other changes.
[**Redacted**]

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

							
	 Revision
	  	Date	  	Sections	  	 Description of Change

	5.0	  	10/10/2011	  	3.3.9.7  
 3.3.9.8
  
 3.3.9.10
  
 3.3.12.10
 3.4.1.1

 
 3.4.1.2

 
 3.4.1.3

 
 3.9.11.1.5

3.9.11.1.7

3.9.11.2
  

3.9.11.3.1
  

3.9.11.1.11.2
  

3.9.11.10

4.6.5.7.2

4.6.5.10.2

4.7
	  	 Increased value to [**Redacted**]
  

Increased [**Redacted**]
  

Refined voltage range [**Redacted**]. Changed section title.
 Corrected and clarified wording of specification
 Clarification added to
[**Redacted**]
  
 Updated [**Redacted**]

 
 New section for [**Redacted**]

 
 Changed [**Redacted**]
 Changed [**Redacted**]
 Removed [**Redacted**]

 
 Added [**Redacted**]

 
 Changed [**Redacted**]

 
 Added further clarifications [**Redacted**]. Retitled.

Specified workmanship testing [**Redacted**].
 Extensive re-write to account for the [**Redacted**]
 Added entry for new paragraph 3.4.1.3
[**Redacted**]

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

							
	 Revision
	  	Date	  	Sections	  	 Description of Change

	6.0	  	10/31/2011	  	Global  
  

 
 3.1.1

 
 3.2.1.4

 
  
  

3.2.1.12

3.2.1.13

3.2.1.14

3.2.2.2

3.2.2.3

3.3

3.4.1.2

3.4.3

3.4.3.1

3.5.1

3.5.2

3.5.3

3.5.4.1

3.5.4.2

3.6.1

3.9.1.1

3.9.1.2

3.9.7

3.9.11.2

3.9.11.3.1

3.9.11.5
 3.10
and all
subparagraphs
 4.6.5.8.1
 4.6.5.8.4
 4.6.5.10.3

 
 4.7
	  	 Labeled requirements that refer only to the main instrument only as Main and those [**Redacted**]

 
 Added new information about [**Redacted**]

 
 Added requirement to cover [**Redacted**]

 
 Changed table to include [**Redacted**]

Added TBD purge fitting for [**Redacted**]

New paragraph for [**Redacted**]
 New
paragraph for [**Redacted**]
 Minor updates to account for [**Redacted**]
 Minor updates to account for [**Redacted**]
 Text added to clarify scope of section with
regard to Main and [**Redacted**]
 Modified to account for [**Redacted**]
 Modified to account for [**Redacted**]
 Modified to account for
[**Redacted**]
 Modified to account for [**Redacted**]
 Modified to account for [**Redacted**]
 Modified to account for
[**Redacted**]
 Modified to account for [**Redacted**]
 Modified to account for [**Redacted**]
 Modified to account for
[**Redacted**]
 Modified to account for [**Redacted**]
 Modified to account for [**Redacted**]
 Modified to account for
[**Redacted**]
 Modified to account for [**Redacted**]
 Modified to account for [**Redacted**]
 Modified to account for
[**Redacted**]
 New requirements added for [**Redacted**]

 
 Modified to account for [**Redacted**]

Modified to account for [**Redacted**]

New [**Redacted**]
  
 Supplemented to account for [**Redacted**].

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

							
	 Revision
	  	Date	  	Sections	  	 Description of Change

	7.0	  	7/19/2012	  	Throughout  
 2.2.1
 2.2.1,
3.3.9.1,
3.3.9.3,
3.3.9.4, and
3.3.9.6

3.2.1.12

3.2.1.13
  

3.2.2.2

3.3.8

3.3.9.4.1
  

3.3.9.4.2
  

3.3.11.5
  

3.3.12.2
  

3.3.12.3

3.4.1.3

3.5.2
  

3.5.4.1
  

3.5.5
  

3.8.4

3.10.3

3.9.11.2
  

3.9.11.3.1

3.10.1

3.10.9.6
  

3.10.12
  

4.6.5.7.2

4.7
	  	 Fixed formatting errors introduced by Word version change.
 Added Reference for [**Redacted**]
 Changed title of [**Redacted**]

 
 Removed TBD and [**Redacted**]

 
 Corrected nominal [**Redacted**]

 
 Removed (TBR) in item d.
 Removed paragraph [**Redacted**]
 Changed [**Redacted**]

 
 Changed [**Redacted**]

 
 Deleted [**Redacted**]

 
 Extensively revised to [**Redacted**]

 
 Clarified applicability [**Redacted**]

Add exception (c) [**Redacted**]
 Changed
terminology in Tables [**Redacted**]
  
 Modified paragraph to refer to
new [**Redacted**]
  
 Separated Operating Cycle requirements for Main
and [**Redacted**]
 Added [**Redacted**]
 Corrected typo. Changed [**Redacted**]
 Clarified definition of Max Operational Range of
[**Redacted**]. Removed TBRs for max operational and survival temperatures [**Redacted**]
 Changed to allow for new
[**Redacted**]
 Changed table reference from 3.3.11-2 to 3.10.10-1.
 Relaxed tolerance on [**Redacted**]
  
 Added [**Redacted**]
  

Added “no greater than” to sweep rate.

Added lines for new items omitted from Rev. 6.0 and fixed formatting issues.

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
  

							
	 Revision
	  	Date	  	Sections	  	 Description of Change

	8.0	  	5/8/2013	  	Change Record
 3.2.1.15

3.3.9.10
  

3.4.1.1

3.4.1.2
  

3.5.2
  

3.5.3 and 3.5.4
  

3.5.4.2
  

3.9.11.2
  

3.9.11.3.1

3.9.11.5.2

3.9.11.6

3.10.20
  

3.10.31

4.6.5.7.1
  

4.6.5.8.1

4.6.5.10.1
  

4.6.5.10.2

4.6.5.10.3
  

4.6.6.1

4.6.6.3

4.7
	  	 Fixed change box for Rev. 7.0 for 3.2.1.12, 3.2.1.13, and 3.2.2.2
 New section to specify alignment cube.
 Changed to show minimum and maximum voltage verification
for shutter testing.
 Modified [**Redacted**].
 Updated Table 3.4.1-1 per agreement. Made FPU values for reference only. Updated Table 3.4.1-4 to account for [**Redacted**].
 Added clarifying phrases to Table 3.5.2-2. Revised transition times in Table 3.5.2-4 and removed TBRs.
 Corrected formatting error which caused the last bullet of 3.5.3 to become a part of the title of 3.5.4
 Deleted extraneous 3.10.10 from b. Replaced “With” with “and with”.
 Updated
Table 3.9.11-8 and Rationale/Info table to correct DPU and PSU interface temperatures, add separate row for RCSS, and revise values for AUX FPU, with test agreements in footnote.
 Update to Table 3.9.11-9 for [**Redacted**].
 Removed explicit analysis reporting
requirement.
 Updated obsolete web link

Corrected typo. Moved extraneous [**Redacted**] at beginning to correct location.
 Revision of requirement to more accurately state need.
 Added sentence to the end of fourth
paragraph to allow for [**Redacted**]with DG approval.
 Added words to Table 4.6.5-1, under [**Redacted**]

Updated item d to allow [**Redacted**]. Updated test modulations in Table 4.6.5-2.
 Updated to allow [**Redacted**].
 Updated item d to include reference to the new Table
3.9.11-10a. Updated item e to allow [**Redacted**].
 Sentence added to allow reduced test matrix.

Reduced number of [**Redacted**].
 Added
[**Redacted**]. Removed T from 3.10.1EX-10.60

 EXHIBIT 10.60 
 FOIA CONFIDENTIAL TREATMENT REQUESTED 
 PORTIONS OF THE EXHIBIT MARKED BY
[**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 HM0210-10-C-0002-P00035 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 

WHEN SEPARATED FROM ATTACHMENT 1 
  

							
	  	  	This Table is UNCLASSIFIED
				
	 CLIN
	  	Maximum Total Price	 	Obligated Amount	 	Unfunded Amount
	CLIN Series 0100	  		 		 	
	0101	  	$250,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	0102	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0103	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0104	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0105	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0106	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 2
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	CLIN Series 0200	  		 		 	
	0201	  	$250,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	0202	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0203	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0204	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0205	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0206	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	[**Redacted**]	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 3
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	CLIN Series 0300	  		 		 	
	0301	  	$250,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	0302	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0303	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0304	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0305	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0306	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	[**Redacted**]	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 4
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	CLIN Series 0400	  		 		 	
	0401	  	$300,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	0402	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0403	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0404	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0405	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0406	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	[**Redacted**]	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 5
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	CLIN Series 0500	  		 		 	
	0501	  	$300,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	0502	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0503	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0504	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0505	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0506	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	[**Redacted**]	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 6
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]

 Contract Page 24 of 63 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
 HM0210-10-C-0002-P00035 

UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 
  

							
	  	  	This Table is UNCLASSIFIED
				
	 CLIN
	  	Maximum Total Price	 	Obligated Amount	 	Unfunded Amount
	CLIN Series 0600	  		 		 	
	0601	  	$300,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	0602	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0603	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0604	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0605	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0606	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 7
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	CLIN Series 0700	  		 		 	
	0701	  	$300,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	0702	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0703	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0704	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0705	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0706	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	[**Redacted**]	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 8
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	CLIN Series 0800	  		 		 	
	0801	  	$300,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	0802	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0803	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0804	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0805	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0806	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	[**Redacted**]	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 9
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	CLIN Series 0900	  		 		 	
	0901	  	$300,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	0902	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0903	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0904	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0905	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	0906	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	[**Redacted**]	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 10
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	Total Contract Value with Options	  	$3,558,547,452.00	 	[**Redacted**]	 	[**Redacted**]

  
 Contract Page
25 of 63 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
 HM0210-10-C-0002-P00035 

UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 
  

	B.8	(U) CLIN DESCRIPTION 

 (U)
In accordance with this contract, the Contractor shall furnish all materials, labor, equipment and facilities, except as specified herein to be furnished by the Government, and shall do all that which is necessary or incidental to the satisfactory
and timely performance of CLINs 0001 through 0006 (and Option CLINs if exercised) as stated above. 
  

	B.9	(U) CONTRACT TYPE 

 (U)
This is a hybrid Firm Fixed Price and Time and Material contract (predominately FFP), with base and option periods as specified in Section/Paragraph F.5. 
  

	(U)	OPTION PERIODS 

  

	B.10	(U) OPTION CLINs 0101, 0201, 0301, 0401, 0501, 0601, 0701, 0801, AND 0901 – COMMERCIAL SATELLITE IMAGERY—SERVICE LEVEL AGREEMENT FOR PIXEL &
IMAGERY ACQUISITION/OPERATIONS (BASELINE COLLECTION CAPACITY) 

  
 Contract Page
26 of 63 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
 HM0210-10-C-0002-P00035 

UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 
  

											
		  	This Table is UNCLASSIFIED
						
	 Action
	  	CLIN	 	ACRN	 	Fund Cite	 	Obligated
Funding	 	Cumulative
Total
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	

  
 Contract Page
35b of 63 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
 HM0210-10-C-0002-P00036 

UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 
  

							
	This Table is UNCLASSIFIED
				
	 CLIN
	  	Maximum Total Price	 	Obligated Amount	 	Unfunded Amount
	 CLIN Series 0100
	  		 		 	
	 0101
	  	$250,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	 0102
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0103
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0104
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0105
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0106
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 2
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 CLIN Series 0200
	  		 		 	
	 0201
	  	$250,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	 0202
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0203
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0204
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0205
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0206
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 3
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 CLIN Series 0300
	  		 		 	
	 0301
	  	$250,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	 0302
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0303
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0304
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0305
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0306
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 4
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 CLIN Series 0400
	  		 		 	
	 0401
	  	$300,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	 0402
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0403
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0404
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0405
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0406
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 5
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 CLIN Series 0500
	  		 		 	
	 0501
	  	$300,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	 0502
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0503
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0504
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0505
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0506
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 6
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]

  
 Contract Page
24 of 63 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
 HM0210-10-C-0002-P00036 

UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 
  

							
	This Table is UNCLASSIFIED
				
	 CLIN
	  	Maximum Total Price	 	Obligated Amount	 	Unfunded Amount
	 CLIN Series 0600
	  		 		 	
	 0601
	  	$300,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	 0602
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0603
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0604
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0605
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0606
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 7
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 CLIN Series 0700
	  		 		 	
	 0701
	  	$300,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	 0702
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0703
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0704
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0705
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0706
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 8
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 CLIN Series 0800
	  		 		 	
	 0801
	  	$300,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	 0802
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0803
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0804
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0805
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0806
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 9
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 CLIN Series 0900
	  		 		 	
	 0901
	  	$300,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	 0902
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0903
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0904
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0905
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0906
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 10
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Total Contract Value with Options
	  	$3,558,547,452.00	 	[**Redacted**]	 	[**Redacted**]

  
 Contract Page
25 of 63 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
 HM0210-10-C-0002-P00036 

UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 
  

	B.8 	(U) CLIN DESCRIPTION 

 (U)
In accordance with this contract, the Contractor shall furnish all materials, labor, equipment and facilities, except as specified herein to be furnished by the Government, and shall do all that which is necessary or incidental to the satisfactory
and timely performance of CLINs 0001 through 0006 (and Option CLINs if exercised) as stated above. 
  

	B.9 	(U) CONTRACT TYPE 

 (U)
This is a hybrid Firm Fixed Price and Time and Material contract (predominately FFP), with base and option periods as specified in Section/Paragraph F.5. 
  

	(U)	OPTION PERIODS 

  

	B.10 	(U) OPTION CLINs 0101, 0201, 0301, 0401, 0501, 0601, 0701, 0801, AND 0901 – COMMERCIAL SATELLITE IMAGERY—SERVICE LEVEL AGREEMENT FOR PIXEL &
IMAGERY ACQUISITION/OPERATIONS (BASELINE COLLECTION CAPACITY) 

  
 Contract Page
26 of 63 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
 HM0210-10-C-0002-P00036 

UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 
  

											
	 This Table is UNCLASSIFIED

						
	 Action
	  	CLIN	 	ACRN	 	Fund
Cite	 	Obligated
Funding	 	Cumulative
Total
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	

  
 Contract Page
35b of 63 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
 HM0210-10-C-0002-P00037 

UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 
  

							
	 This Table is UNCLASSIFIED

				
	 CLIN
	  	 Maximum Total Price
	  	 Obligated Amount
	  	 Unfunded Amount

	CLIN Series 0100	  		  		  	
	 0101
	  	$250,000,000.00	  	[**Redacted**]	  	[**Redacted**]
	 0102
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0103
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0104
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0105
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0106
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 Subtotal Contract Year 2
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	CLIN Series 0200	  		  		  	
	 0201
	  	$250,000,000.00	  	[**Redacted**]	  	[**Redacted**]
	 0202
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0203
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0204
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0205
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0206
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 Subtotal Contract Year 3
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	CLIN Series 0300	  		  		  	
	 0301
	  	$250,000,000.00	  	[**Redacted**]	  	[**Redacted**]
	 0302
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0303
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0304
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0305
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0306
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 Subtotal Contract Year 4
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	CLIN Series 0400	  		  		  	
	 0401
	  	$300,000,000.00	  	[**Redacted**]	  	[**Redacted**]
	 0402
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0403
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0404
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0405
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0406
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 Subtotal Contract Year 5
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	CLIN Series 0500	  		  		  	
	 0501
	  	$300,000,000.00	  	[**Redacted**]	  	[**Redacted**]
	 0502
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0503
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0504
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0505
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0506
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 Subtotal Contract Year 6
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]

  
 Contract Page
24 of 63 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
 HM0210-10-C-0002-P00037 

UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 
  

							
	  	  	This Table is UNCLASSIFIED
				
	 CLIN
	  	 Maximum Total Price
	  	 Obligated Amount
	  	 Unfunded Amount

	CLIN Series 0600	  		  		  	
	 0601
	  	$300,000,000.00	  	[**Redacted**]	  	[**Redacted**]
	 0602
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0603
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0604
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0605
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0606
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 Subtotal Contract Year 7
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	CLIN Series 0700	  		  		  	
	 0701
	  	$300,000,000.00	  	[**Redacted**]	  	[**Redacted**]
	 0702
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0703
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0704
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0705
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0706
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 Subtotal Contract Year 8
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	CLIN Series 0800	  		  		  	
	 0801
	  	$300,000,000.00	  	[**Redacted**]	  	[**Redacted**]
	 0802
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0803
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0804
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0805
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0806
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 Subtotal Contract Year 9
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	CLIN Series 0900	  		  		  	
	 0901
	  	$300,000,000.00	  	[**Redacted**]	  	[**Redacted**]
	 0902
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0903
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0904
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0905
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 0906
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 Subtotal Contract Year 10
	  	[**Redacted**]	  	[**Redacted**]	  	[**Redacted**]
	 Total Contract Value with Options
	  	$3,558,547,452.00	  	[**Redacted**]	  	[**Redacted**]

  
 Contract Page
25 of 63 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
 HM0210-10-C-0002-P00037 

UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 
  

	B.8	(U) CLIN DESCRIPTION 

(U) In accordance with this contract, the Contractor shall furnish all materials, labor, equipment and facilities, except as specified
herein to be furnished by the Government, and shall do all that which is necessary or incidental to the satisfactory and timely performance of CLINs 0001 through 0006 (and Option CLINs if exercised) as stated above. 

 

	B.9	(U) CONTRACT TYPE 

(U) This is a hybrid Firm Fixed Price and Time and Material contract (predominately FFP), with base and option periods as specified in
Section/Paragraph F.5. 
  

	(U)	OPTION PERIODS 

  

	B.10	(U) OPTION CLINs 0101, 0201, 0301, 0401, 0501, 0601, 0701, 0801, AND 0901 – COMMERCIAL SATELLITE IMAGERY—SERVICE LEVEL AGREEMENT FOR PIXEL &
IMAGERY ACQUISITION/OPERATIONS (BASELINE COLLECTION CAPACITY) 

  
 Contract Page
26 of 63 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
 HM0210-10-C-0002-P00037 

UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 
  

 This Table is UNCLASSIFIED 

 

											
	 Action
	  	CLIN	 	ACRN	 	Fund
Cite	 	Obligated
Funding	 	Cumulative
Total
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	

  
 Contract Page
35b of 63 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
 HM0210-10-C-0002-P00038 

UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 
  

	B.5	(U) CLIN 0005: COMMERCIAL SATELLITE IMAGERY—PHYSICAL MEDIA DELIVERY 

 (U) The scope of effort for this CLIN is defined in Contract Attachment 1, EnhancedView Imagery Acquisition Statement of Work. This CLIN has a ceiling value of [**Redacted**]. The sum of all items
provided herein and invoiced for shall not exceed [**Redacted**]. 
 (U) Minimum Amount: $0.00 

(U) Maximum Amount: [**Redacted**] 
 (U)
CLIN 0005 is an indefinite-quantity ordering CLIN for the supplies or services and prices specified in the Statement of Work to support the storage and dissemination of imagery and image products on media, and is effective for the entire period of
performance. Delivery or performance shall be made only as authorized by the Contracting Officer, the Contracting Officer’s Representative, or other government official as designated by the Contracting Officer. The Contractor shall furnish to
the Government, when and if ordered, the supplies specified in CLIN 0005 up to and including the amount designated as the “maximum.” The Government has no minimum order obligations. 

 

	B.6	(U) CLIN 0006: COMMERCIAL SATELLITE IMAGERY—SYSTEM ENGINEERING SERVICES SUPPORT 

 (U) The scope of effort for this CLIN is defined in Contract Attachment 1, EnhancedView Imagery Acquisition Statement of Work. This CLIN has a ceiling value of [**Redacted**]. The sum of all effort
provided herein and invoiced for shall not exceed [**Redacted**]. CLIN 0006 is a time and material (T&M) CLIN for System Engineering Services. T&M support shall be provided as directed by the Contracting Officer. 

(U) CLIN 0006 will be incrementally funded in accordance with NGA budget and policy provisions. The Government’s and the Contractor’s
continuing obligations under this CLIN is contingent upon the availability of appropriated funds from which payment for contract purposes can be made. No legal liability on the part of the Government for any payment or on the part of the Contractor
for any performance under any task placed under this CLIN may arise until funds are made available to the Contracting Officer for such tasks and until the Contractor receives notice of such availability in writing by the Contracting Officer and the
Contracting Officer modifies the contract to expressly obligate the additional funds. 
 This Table is UNCLASSIFIED 

 

							
	 CLIN
	  	Maximum Total
Price	 	Obligated
Amount	 	Unfunded
Amount
	CLIN Series 0000	  		 		 	
	 0001
	  	$250,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	 0002
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0003
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0004
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0005
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0006
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0007
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Base Contract Year 1
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	CLIN Series 0100	  		 		 	

  
 Contract Page
24 of 63 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
 HM0210-10-C-0002-P00038 

UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 
  

 This Table is UNCLASSIFIED 

 

							
	 CLIN
	  	Maximum Total
Price	 	Obligated
Amount	 	Unfunded
Amount
	CLIN Series 0000	  		 		 	
	 0101
	  	$250,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	 0102
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0103
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0104
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0105
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0106
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 2
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	CLIN Series 0200	  		 		 	
	 0201
	  	$250,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	 0202
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0203
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0204
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0205
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0206
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 3
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	CLIN Series 0300	  		 		 	
	 0301
	  	$250,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	 0302
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0303
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0304
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0305
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0306
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 4
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	CLIN Series 0400	  		 		 	
	 0401
	  	$300,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	 0402
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0403
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0404
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0405
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0406
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 5
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	CLIN Series 0500	  		 		 	
	 0501
	  	$300,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	 0502
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0503
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0504
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0505
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0506
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 6
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]

  
 Contract Page
25 of 63 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
 HM0210-10-C-0002-P00038 

UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 
  

 This Table is UNCLASSIFIED 

 

							
	 CLIN
	  	Maximum Total
Price	 	Obligated
Amount	 	Unfunded
Amount
	CLIN Series 0000	  		 		 	
	CLIN Series 0600	  		 		 	
	 0601
	  	$300,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	 0602
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0603
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0604
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0605
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0606
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 7
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	CLIN Series 0700	  		 		 	
	 0701
	  	$300,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	 0702
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0703
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0704
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0705
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0706
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 8
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	CLIN Series 0800	  		 		 	
	 0801
	  	$300,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	 0802
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0803
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0804
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0805
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0806
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 9
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	CLIN Series 0900	  		 		 	
	 0901
	  	$300,000,000.00	 	[**Redacted**]	 	[**Redacted**]
	 0902
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0903
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0904
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0905
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 0906
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Subtotal Contract Year 10
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
	 Total Contract Value with Options
	  	$3,558,547,452.00	 	[**Redacted**]	 	[**Redacted**]

  
 Contract Page
26 of 63 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
 HM0210-10-C-0002-P00038 

UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 
  

	B.8	(U) CLIN DESCRIPTION 

 (U)
In accordance with this contract, the Contractor shall furnish all materials, labor, equipment and facilities, except as specified herein to be furnished by the Government, and shall do all that which is necessary or incidental to the satisfactory
and timely performance of CLINs 0001 through 0006 (and Option CLINs if exercised) as stated above. 
  

	B.9	(U) CONTRACT TYPE 

 (U)
This is a hybrid Firm Fixed Price and Time and Material contract (predominately FFP), with base and option periods as specified in Section/Paragraph F.5. 
  

	(U)	OPTION PERIODS 

  

	B.10	(U) OPTION CLINs 0101, 0201, 0301, 0401, 0501, 0601, 0701, 0801, AND 0901 – COMMERCIAL SATELLITE IMAGERY—SERVICE LEVEL AGREEMENT FOR PIXEL &
IMAGERY ACQUISITION/OPERATIONS (BASELINE COLLECTION CAPACITY) 

 (U) The scope of this FFP CLIN for the
acquisition and delivery of imagery and associated imagery support data under a SLA from the Contractor’s satellite constellation is defined in Contract Attachment 1, EnhancedView Imagery Acquisition Statement of Work, and in accordance with
Special Contract Requirement H.24, Exercise of Options. This effort is priced at the amounts set forth below. 
 This Table is
UNCLASSIFIED 
 Options: Contract Years 2 through 10 

 

							
	 CLIN Series 0x01
	  	 Baseline Quantity

(sqnmi/day)
	  	 Firm Fixed Price
(12 Months)
	 
	 Option CLIN 0101 (Contract Year 2) [**Redacted**]
	  	[**Redacted**]	  	$	250,000,000.00	  
	
                        
                                     
[**Redacted**]
	  	[**Redacted**]	  			
	 Option CLIN 0201 (Contract Year 3)
	  	[**Redacted**]	  	$	250,000,000.00	  
	 Option CLIN 0301 (Contract Year 4)
	  	[**Redacted**]	  	$	250,000,000.00	  
	 [**Redacted**]
	  		  			
	 Option CLIN 0401 (Contract Year 5) *
	  	[**Redacted**]	  	$	300,000,000.00	  
	 Option CLIN 0501 (Contract Year 6) *
	  	[**Redacted**]	  	$	300,000,000.00	  
	 Option CLIN 0601 (Contract Year 7) *
	  	[**Redacted**]	  	$	300,000,000.00	  
	 Option CLIN 0701 (Contract Year 8) *
	  	[**Redacted**]	  	$	300,000,000.00	  
	 Option CLIN 0801 (Contract Year 9) *
	  	[**Redacted**]	  	$	300,000,000.00	  
	 Option CLIN 0901 (Contract Year 10) *
	  	[**Redacted**]	  	$	300,000,000.00	  

 (U) Funds are not presently available for the full amount of Option CLINs 0101, 0201, 0301, 0401, 0501, 0601, 0701, 0801,
and 0901 (if exercised). The Government intends to incrementally fund these Option CLINs. The Government’s and the Contractor’s continuing obligations under this Contract are contingent upon the availability of appropriated funds from
which payment for contract purposes can be made. No legal liability on the part of the Government for any payment or on the part of the Contractor for any performance under any order placed under this Contract may arise until funds are made
available to the Contracting Officer for such orders and until the Contractor receives notice of such availability in writing from the Contracting Officer and the Contracting Officer modifies the contract to expressly obligate the additional funds.

  
 Contract Page
27 of 63 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
 HM0210-10-C-0002-P00038 

UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 
  

	B.11 	(U) OPTION [**Redacted**] 

  

	B.12 	(U) OPTION [**Redacted**] 

  

	B.13 	(U) OPTION [**Redacted**] 

  

	B.14 	(U) OPTION CLINs 0104, 0204, 0304, 0404, 0504, 0604, 0704, 0804, AND 0904: COMMERCIAL SATELLITE IMAGERY—VALUE-ADDED PRODUCTS AND SERVICES

 (U) The scope of effort for this CLIN Series is defined in Contract Attachment 1, EnhancedView Imagery Acquisition
Statement of Work, and in accordance with Special Contract Requirement H.24, Exercise of Options. This effort is estimated at the amounts set forth below. These Option CLINs have a ceiling value for Contract Year 2 THROUGH 10 as indicated below. The
sum of all items ordered herein and invoiced for shall not exceed each Option CLINs’ maximum value. 
 (U) Minimum Amount: $0.00 per Option
CLIN 
 (U) Maximum Amount: [**Redacted**] per Option CLIN 0104 
 (U) Maximum Amount: [**Redacted**] per Option CLIN 0204 
 (U) Maximum Amount:
[**Redacted**] per Option CLIN 0304 
 (U) Maximum Amount: [**Redacted**] per Option CLINs 0404 and 0504 

(U) Maximum Amount: [**Redacted**] per Option CLINs 0604, 0704, 0804 and through 0904 
 (U) Option CLIN 0104, 0204, 0304, 0404, 0504, 0604, 0704, 0804, and 0904 are indefinite-quantity ordering CLINs for the supplies or services and prices as specified in the Statement of Work or in
separately issued contractual documents and are effective for the entire period of performance or as otherwise specified. Ordering will be accomplished in accordance with Special Contract Requirement H.7, Ordering Procedures. Delivery or performance
shall be made only as authorized by orders issued in accordance with the Statement of Work, Section C. The Contractor shall furnish to the Government, when and if ordered, the supplies or services specified herein up to and including the amount
designated as the “maximum.” The Government has no minimum order obligations. Except for the limitations in the value specified as the maximum amount, there is no limit on the number of orders that may be issued. The Government may issue
orders requiring delivery to multiple destinations or performance at multiple locations. (Funding obligations for this CLIN may occur via Standard Form 30s, DD Form 1155s, or other forms as determined at the time of award of the specific value-added
requirement.) 
  

	B.15 	(U) OPTION CLINs 0105, 0205, 0305, 0405, 0505, 0605, 0705, 0805, AND 0905: COMMERCIAL SATELLITE IMAGERY—PHYSICAL MEDIA DELIVERY 

(U) The scope of effort for this CLIN Series is defined in Contract Attachment 1, EnhancedView Imagery Acquisition Statement of Work, and in accordance
with Special Contract Requirement H.24, Exercise of Options. This effort is estimated at the amounts set forth below. These Option CLINs have a ceiling value for Contract Year 2 through 10 as indicated below. The sum of all items provided herein and
invoiced for shall not exceed each Option CLINs’ maximum value. 
 (U) Minimum Amount: $0.00 per Option CLIN 

(U) Maximum Amount: [**Redacted**] per Option CLIN 0105 
 (U) Maximum Amount: [**Redacted**] per Option CLIN 0205 

  
 Contract Page
28 of 63 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
 HM0210-10-C-0002-P00038 

UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 
  

 (U) Maximum Amount: [**Redacted**] per Option CLIN 0305 

(U) Maximum Amount: [**Redacted**] per Option CLINs 0205, 0305, 0405, 0505, 0605, 0705, 0805 and 0905 

(U) Option CLINs 0105, 0205, 0305, 0405, 0505, 0605, 0705, 0805, and 0905 are indefinite-quantity ordering CLINs for the supplies or services and prices
specified herein to support the storage and dissemination of imagery, and image products on media, and are effective for the entire period of performance. Delivery or performance shall be made only as authorized by the Contracting Officer, the
Contracting Officer’s Representative, or other government official as designated by the Contracting Officer. The Contractor shall furnish to the Government, when and if ordered, the supplies or services specified in Option CLINs 0105, 0205,
0305, 0405, 0505, 0605, 0705, 0805, and 0905 up to and including the amount designated as the “maximum.”. The Government has no minimum order obligations. 
  

	B.16 	(U) OPTION CLINs 0106, 0206, 0306, 0406, 0506, 0606, 0706, 0806, AND 0906: COMMERCIAL SATELLITE IMAGERY—SYSTEM ENGINEERING SERVICES SUPPORT

 (U) The scope of effort for this CLIN Series is defined in Contract Attachment 1, EnhancedView Imagery Acquisition Statement
of Work, and in accordance with Special Contract Requirement H.24, Exercise of Options. These Option CLINs have a ceiling value as indicated below. The sum of all effort provided herein and invoiced for shall not exceed the ceiling value per Option
CLIN. Option CLINs 0106, 0206, 0306, 0406, 0506, 0606, 0706, 0806, and 0906 are T&M CLINs for System Engineering Services Support. T&M support shall be provided as directed by the Contracting Officer. 

(U) Ceiling Value: [**Redacted**] per Option CLIN 0106 
 (U) Ceiling Value: [**Redacted**] per Option CLIN 0206 
 (U) Ceiling Value:
[**Redacted**] per Option CLIN 0306 
 (U) Ceiling Value: [**Redacted**] per Option CLINs 0406, 0506, 0606, 0806
and 0906 
 (U) These Option CLINs will be incrementally funded in accordance with NGA budget and policy provisions. The Government’s and
the Contractor’s continuing obligations under these CLINs are contingent upon the availability of appropriated funds from which payment for contract purposes can be made. No legal liability on the part of the Government for any payment or on
the part of the Contractor for any performance under any task placed under these Option CLINs may arise until funds are made available to the Contracting Officer for such tasks and until the Contractor receives notice of such availability in writing
by the Contracting Officer and the Contracting Officer modifies the contract to expressly obligate the additional funds. 
 [**Redacted**]

 [**Redacted**] 

  
 Contract Page
29 of 63 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 

 FOIA CONFIDENTIAL TREATMENT REQUESTED 

PORTIONS OF THE EXHIBIT MARKED BY [**Redacted**] HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION 
 HM0210-10-C-0002-P00038 

UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1 
  

											
		  	This Table is UNCLASSIFIED
						
	 Action
	  	CLIN	 	ACRN	 	Fund Cite	 	Obligated
Funding	 	Cumulative
Total
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	
	 [**Redacted**]
	  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	[**Redacted**]	 	
		  		 		 	[**Redacted**]	 	[**Redacted**]	 	

  
 Contract Page
35b of 63 
 UNCLASSIFIED//FOR OFFICIAL USE ONLY 
 WHEN SEPARATED FROM ATTACHMENT 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]